Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer

Breast Cancer Research and Treatment

Volumn 132, Issue 1, 2012, Pages 215-223

  Montero, A J ^a   Diaz Montero, C M ^a   Deutsch, Y E ^a   Hurley, J ^a   Koniaris, L G ^b   Rumboldt, T ^c   Yasir, S ^a   Jorda, M ^a   Garret Mayer, E ^c   Avisar, E ^a   Slingerland, J ^a   Silva, O ^a   Welsh, C ^a   Schuhwerk, K ^d   Seo, P ^a   Pegram, M D ^a   Gluck S ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Novelos Therapeutics Inc   (United States)

Author keywords

Anthracycline; Breast cancer; Glutathione analog; MDSC; Myeloid derived suppressor cells; Neoadjuvant; NOV 002; Pathologic complete response; Phase 2; Taxane

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GLUTATHIONE DISULFIDE; NOV 002; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTERY OCCLUSION; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELLULITIS; CLINICAL ARTICLE; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEMORAL ARTERY OCCLUSION; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYELOID DERIVED SUPPRESSOR CELL; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; QUANTITATIVE STUDY; RECURRENCE FREE SURVIVAL; SENSORY NEUROPATHY; SUPPRESSOR CELL; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG COMBINATIONS; FEMALE; GLUTATHIONE DISULFIDE; HUMANS; IMMUNITY, CELLULAR; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857916510     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1889-0     Document Type: Article

References (52)

1. Cabello CM, Lamore SD, Bair WB III, Davis AL, Azimian SM, Wondrak GT (2011) DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma. Free Radic Res 45(3):276-292
2. Montero AJ, Jassem J (2011) Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 71(11):1385-1396
3. Wondrak GT (2009) Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 11(12):3013-3069
4. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ (1997) Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275(5306):1649-1652 (Pubitemid 27120541)
5. Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A, Levy E, Goldwasser F, Panis Y, Soubrane O et al (2005) Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65(3):948-956 (Pubitemid 40216456)
6. Rodrigues MS, Reddy MM, Sattler M (2008) Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. Antioxid Redox Signal 10(10):1813-1848
7. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. Antioxid Redox Signal 10(8):1343-1374
8. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J et al (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10(3):241-252 (Pubitemid 44311067)
9. Glorieux C, Dejeans N, Sid B, Beck R, Calderon PB, Verrax J (2011) Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol 82(10):1384-1390
10. He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J (2009) A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat 113(3): 585-594
11. Yang JC, Lu MC, Lee CL, Chen GY, Lin YY, Chang FR, Wu YC (2011) Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K. Free Radic Biol Med 51(3): 641-657
12. Townsend DM, He L, Hutchens S, Garrett TE, Pazoles CJ, Tew KD (2008) NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance. Cancer Res 68(8):2870 -2877
13. Townsend DM, Pazoles CJ, Tew KD (2008) NOV-002, a mimetic of glutathione disulfide. Expert Opin Investig Drugs 17(7):1075-1083
14. Townsend DM, Tew KD (2009) Pharmacology of a mimetic of glutathione disulfide, NOV-002. Biomed Pharmacother 63(2): 75-78
15. Brigelius-Flohe R (2006) Glutathione peroxidases and redox-regulated transcription factors. Biol Chem 387(10-11):1329-1335
16. Giles GI (2006) The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 12(34):4427-4443
17. Tew KD, Manevich Y, Grek C, Xiong Y, Uys J, Townsend DM (2011) The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. Free Radic Biol Med 51(2):299-313
18. Townsend DM (2007) S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response. Mol Interv 7(6): 313-324
19. Gumireddy K, Pazoles C, Vulfson E (2009) Inhibition of tumor cell invasion and ErbB2/PI3 K signalling pathways by the glutathione disulfide-mimetic NOV-002. Proceedings of the 100th annual meeting of the American Association for Cancer Research, 2009 (Abstract)
20. Townsend DM, Bowers R, Pazoles CJ (2009) NOV-002 suppresses tumor cell growth by modulating redox-sensitive cell signaling. Mol Cancer Ther 8(12 Suppl. 1) (Abstract C30)
21. Bowers R, Townsend D, Manevich Y (2010) The redox modulator NOV-002 inhibits proliferation of ovariantumor cells but increases proliferation of myeloid cells. Proceedings of the 101st annual meeting of the American Association for Cancer Research, 2010 (Abstract)
22. Montero AJ, Naga O, Xu M (2009) Nov-002, a cellular redox modulator, enhances the antitumor effect of adoptively transferred T cells in a murine melanoma model. Mol Cancer Ther 8(12 Suppl. 1) (Abstract C238)
23. Krasner CN, Seiden MV, Penson RT (2008) NOV-002 plus carboplatin in platinum-resistant ovarian cancer. J Clin Oncol 26 (Abstract)
24. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21(22):4165-4174 (Pubitemid 46606185)
25. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24(13):2019-2027 (Pubitemid 46622110)
26. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414-4422 (Pubitemid 350013847)
27. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58(1):49-59
28. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G et al. (2011) A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (Journal Article)
29. Koyama T, Chen H (2008) Proper inference from Simon's two-stage designs. Stat Med 27(16):3145-3154
30. Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT (2010) The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 17(9):2411-2418
31. Tolaney SM, Najita J, Winer EP, Burstein HJ (2008) Lymphopenia associated with adjuvant anthracycline/taxane regimens. Clin Breast Cancer 8(4):352-356
32. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Booser D, Ibrahim N et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284-2293 (Pubitemid 41115384)
33. Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT et al (2005) American joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97(15):1137-1142 (Pubitemid 41511213)
34. Fisher B, Bryant J, Wolmark N,Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A et al (1998) Effect of preoperative chemotherapy on the outcome ofwomenwith operable breast cancer. J Clin Oncol 16(8):2672-2685 (Pubitemid 28363030)
35. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A et al (2005) Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23(28):7098-7104
36. Heys SD, Sarkar T, Hutcheon AW (2005) Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat 90(2):169-185 (Pubitemid 40568900)
37. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F (2006) Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 13(1):38-48
38. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM et al (2007) Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18(5):874-880 (Pubitemid 47054084)
39. Glück S, Ross JS, Royce M, McKenna EF, Jr., Perou CM, Avisar E, Wu L (2011) TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat (Journal Article)
40. Glück S, McKenna EF Jr, Royce M (2008) XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer. Int J Med Sci 5(6):341-346
41. von Minckwitz G, Raab G, Caputo A, Schutte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23(12):2676-2685 (Pubitemid 46179457)
42. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001(30):96-102
43. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Hortobagyi GN et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24(7):1037-1044 (Pubitemid 46638799)
44. Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6(4):229-239 (Pubitemid 40450714)
45. Ruscoe JE, Rosario LA, Wang T, Gate L, Arifoglu P, Wolf CR, Henderson CJ, Ronai Z, Tew KD (2001) Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 298(1):339-345 (Pubitemid 32574545)
46. Pazoles CJ, Gerstein H (2006) NOV-002, a chemoprotectant/ immunomodulator, added to first-line carboplatin/paclitaxel in advanced non-small cell lung cancer (NSCLC): a randomized phase 1/2, open-label, controlled study. J Clin Oncol 24(18S): Pt 1(June 20 Suppl): 668S, (Abstract #17021)
47. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54-61 (Pubitemid 46067386)
48. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G (2008) Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 20(5):504-511
49. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V (2009) IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 182(10):6562-6568
50. Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59(10):1593-1600
51. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW (2011) Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 60(10):1419-1430
52. Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, Dunn M, Urbas P, Daud A, DeConti R et al (2010) Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin- 2 therapy for kidney cancer and melanoma. J Immunother 33(8):817-827